CSL (CHIA:CSL) - Aktienkurs, Nachrichten und Analyse

CSL Aktienübersicht

CSL grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	3/6
Vergangene Leistung	5/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

29% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 12.99% pro Jahr

Die Erträge stiegen im vergangenen Jahr um 20.4%

Risikoanalyse

Hat einen hohen Schuldenstand

CSL Limited Wettbewerber

Telix Pharmaceuticals

ASX:TLX

AU$8.0b

Clinuvel Pharmaceuticals

ASX:CUV

AU$653.8m

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$81.0b

Amgen

NasdaqGS:AMGN

US$150.5b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für CSL
Historische Aktienkurse
Aktueller Aktienkurs	AU$285.81
52-Wochen-Hoch	AU$313.50
52-Wochen-Tief	AU$259.07
Beta	0.30
11 Monat Veränderung	-2.24%
3 Monate Veränderung	-6.95%
1 Jahr Veränderung	8.99%
33 Jahre Veränderung	-6.13%
5 Jahre Veränderung	3.16%
Veränderung seit IPO	315.54%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	CSL	AU Biotechs	AU Markt
7D	4.6%	2.5%	0.8%
1Y	9.0%	11.2%	18.1%

Rendite im Vergleich zur Industrie: CSL unter dem Niveau der Branche Australian Biotechs , die im vergangenen Jahr eine Rendite von 11.2% erzielte.

Rendite vs. Markt: CSL hinter dem Markt Australian zurück, der im vergangenen Jahr eine Rendite von 18.1 erzielte.

Preisvolatilität

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	2.2%
Biotechs Industry Average Movement	9.6%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.2%

Stabiler Aktienkurs: CSL hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: CSLDie wöchentliche Volatilität (2%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1916	32,698	Paul McKenzie	www.csl.com.au

CSL Limited erforscht, entwickelt, produziert, vermarktet und vertreibt Biopharmazeutika und Impfstoffe in Australien, den Vereinigten Staaten, Deutschland, dem Vereinigten Königreich, der Schweiz, China, Hongkong und international. Das Unternehmen ist in den Segmenten CSL Behring, CSL Seqirus und CSL Vifor tätig. Das Segment CSL Behring bietet Plasmaprodukte, Gentherapien und Rekombinanten an.

CSL Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von CSL im Vergleich zum Marktanteil des Unternehmens?
CSL grundlegende Statistiken
Marktanteil	AU$138.09b
Gewinn(TTM)	AU$4.07b
Umsatz(TTM)	AU$22.78b

34.0x

Kurs-Gewinn-Verhältnis

6.1x

Kurs-Umsatz-Verhältnis

Ist CSL zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
CSL Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$14.80b
Kosten der Einnahmen	US$7.10b
Bruttogewinn	US$7.71b
Sonstige Ausgaben	US$5.06b
Umsatz	US$2.64b

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

Feb 10, 2025

Gewinn per Aktie (EPS)	5.46
Bruttomarge	52.06%
Nettogewinnspanne	17.85%
Schulden/Eigenkapital-Verhältnis	54.2%

Wie hat sich CSL auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

1.4%

Aktuelle Dividendenrendite

48%

Ausschüttungsquote

CSL Aktienübersicht

Belohnungen

Risikoanalyse

CSL Limited Wettbewerber

ASX:TLX

AU$8.0b

ASX:CUV

AU$653.8m

NasdaqGS:REGN

US$81.0b

NasdaqGS:AMGN

US$150.5b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

Recent updates

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022)

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Upcoming dividend of US$1.07 per share at 1.1% yield

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Independent Non Executive Director recently bought AU$74k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock

Upcoming dividend of US$1.18 per share

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 20% undervalued

Now 21% undervalued after recent price drop

Upcoming dividend of US$1.04 per share

Independent Non-Executive Director recently bought AU$54k worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Centerview Reportedly Role in Vifor Sale

Erträge & Einnahmen